{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:01:41Z","timestamp":1792450901743,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009300.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000}}],"reference-count":174,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009300.pub3","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T07:33:25Z","timestamp":1686728005000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Complement inhibitors for age-related macular degeneration"],"prefix":"10.1002","volume":"2023","author":[{"given":"Nikolaos","family":"Tzoumas","sequence":"additional","affiliation":[{"name":"Biosciences Institute; Newcastle University; Newcastle-upon-Tyne UK"},{"name":"Sunderland Eye Infirmary; Sunderland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Riding","sequence":"additional","affiliation":[{"name":"Biosciences Institute, Newcastle University; Newcastle-upon-Tyne UK"},{"name":"North Middlesex University Hospital NHS Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Williams","sequence":"additional","affiliation":[{"name":"School of Medicine, Dentistry and Biomedical Science, Queen\u2019s University of Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David HW","family":"Steel","sequence":"additional","affiliation":[{"name":"Biosciences Institute; Newcastle University; Newcastle-upon-Tyne UK"},{"name":"Sunderland Eye Infirmary; Sunderland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"10.1002\/14651858.CD009300.pub3-BIB0001|cit1","unstructured":"Csaky KG Westby K Rezaei K Avacincaptad pegol, a novel C5 inhibitor, significantly reduces the mean rate of geographic atrophy growth in a pivotal clinical trial Investigative Ophthalmology and Visual Science 2020 61 7 ARVO E abstract 1943"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0003|cit3","unstructured":"Sheth V Avacincaptad pegol, a novel C5 inhibitor, demonstrates a continued reduction in the mean rate of geographic atrophy growth: 18-month results from the GATHER1 clinical trial Investigative Ophthalmology and Visual Science 2021 62 8 ARVO E abstract 333"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0004|cit4","unstructured":"CLG561 proof-of-concept study as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (GA) clinicaltrials.gov\/ct2\/show\/NCT02515942"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3928\/23258160-20131217-01","article-title":"Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration","volume":"45","author":"Garcia Filho","year":"2014","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1167\/iovs.13-13199","article-title":"OCT minimum intensity as a predictor of geographic atrophy enlargement","volume":"55","author":"Stetson","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3928\/23258160-20150422-03","article-title":"Comparison of geographic atrophy growth rates using different imaging modalities in the COMPLETE study","volume":"46","author":"Yehoshua","year":"2015","journal-title":"Ophthalmic Surgery, Lasers & Imaging Retina"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2014.08.035","article-title":"Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration","volume":"122","author":"Hariri","year":"2015","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD009300.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1167\/iovs.16-20361","article-title":"Functional Reading Independence (FRI) Index: a new patient-reported outcome measure for patients with geographic atrophy","volume":"57","author":"Kimel","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2018.03.006","article-title":"Reliability and construct validity of the NEI VFQ-25 in a subset of patients with geographic atrophy from the phase 2 Mahalo Study","volume":"190","author":"Sivaprasad","year":"2018","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"eaaf1443","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Science Translation Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.oret.2020.01.019","article-title":"Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmology Retina"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0015|cit15","unstructured":"Long-term safety of lampalizumab intravitreal (ITV) injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (OMASPECT) clinicaltrials.gov\/ct2\/show\/NCT02745119"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0016|cit16","unstructured":"Pieramici D Holz F Heier JS Sadda SR Busbee BG Chew EY Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs) Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 4948"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.oret.2020.01.019","article-title":"Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmology Retina"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0019|cit19","unstructured":"Long-term safety of lampalizumab intravitreal (ITV) injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (OMASPECT)\u00a0 clinicaltrials.gov\/ct2\/show\/NCT02745119"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0020|cit20","unstructured":"Pieramici D Holz F Heier JS Sadda SR Busbee BG Chew EY Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs) Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 4948"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0021|cit21","unstructured":"Intravitreal LFG316 in patients with age-related macular degeneration (AMD) clinicaltrials.gov\/ct2\/show\/record\/NCT01527500"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0022|cit22","unstructured":"Bogunovic H Lachinov D Mai J Reiter GS Riedl S Vogl WD Predictive identification of the fastest progressing geographic atrophy lesions based on deep learning in the phase 2 FILLY clinical trial of pegcetacoplan Investigative Ophthalmology and Visual Science 2021 62 8 ARVO E abstract 129"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0023|cit23","unstructured":"Chakravarthy U Ip M Nittala M Metlapally R Ribiero R Sadda S Impact of pegcetacoplan on progression of nascent atrophy in age-related macular degeneration (AMD) Investigative Ophthalmology and Visual Science 2021 62 8 ARVO E abstract 1213"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD009300.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2217\/imt-2022-0078","article-title":"Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study","volume":"14","author":"Liao","year":"2022","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaophthalmol.2021.6067","article-title":"Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the FILLY randomized clinical trial","volume":"140","author":"Nittala","year":"2022","journal-title":"JAMA Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD009300.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.oret.2022.05.030","article-title":"The effect of pegcetacoplan treatment on photoreceptor maintenance in geographic atrophy monitored by artificial intelligence-based OCT analysis","volume":"6","author":"Riedl","year":"2022","journal-title":"Ophthalmology Retina"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0028|cit28","unstructured":"Schmidt-Erfurth U Mai J Reiter GS Riedl S Lachinov D Vogl WD AI-based quantification of photoreceptor maintenance in the treatment of geographic atrophy secondary to AMD in the FILLY trial Investigative Ophthalmology and Visual Science 2021 62 8 ARVO E abstract 236"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0029|cit29","unstructured":"Steinle N Hamdani M Evaluation of baseline factors on progression in a large phase-2 clinical trial for geographic atrophy (FILLY Study) Investigative Ophthalmology and Visual Science 2019 60 9 ARVO E abstract 973"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2021.02.031","article-title":"Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan","volume":"227","author":"Steinle","year":"2021","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0031|cit31","unstructured":"Vogl WD Bogunovic H Mai J Reiter GS Riedl S Lachinov D Topographic effects on AI-quantified regional progression in the FILLY trial of pegcetacoplan (APL-2) for treatment of geographic atrophy secondary to AMD Investigative Ophthalmology and Visual Science 2021 62 8 ARVO E abstract 128"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.oret.2022.08.003","article-title":"Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning","volume":"7","author":"Vogl","year":"2023","journal-title":"Ophthalmology Retina"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0033|cit33","unstructured":"Wykoff CC Grossi F APL-2, a complement C3 inhibitor, slows the growth of geographic atrophy secondary to AMD: 18-month results of a phase 2 trial (FILLY) Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 72"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0035|cit35","unstructured":"Goldberg R Heier JS Wykoff CC Staurenghi G Singh RP Steinle N Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies Investigative Ophthalmology and Visual Science 2022 63 7 ARVO E abstract 1500"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0036|cit36","unstructured":"Wykoff CC Treatment of geographic atrophy secondary to age-related macular degeneration with pegcetacoplan: updates on the randomized phase 3 DERBY and OAKS trials American Academy of Ophthalmology Annual Meeting, New Orleans, LA, United States 2021"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0037|cit37","unstructured":"Goldberg R Heier JS Wykoff CC Staurenghi G Singh RP Steinle N Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies Investigative Ophthalmology and Visual Science 2022 63 7 ARVO E abstract 1500"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0038|cit38","unstructured":"Wykoff CC Treatment of geographic atrophy secondary to age-related macular degeneration with pegcetacoplan: updates on the randomized phase 3 DERBY and OAKS trials American Academy of Ophthalmology Annual Meeting, New Orleans, LA, United States 2021 2021"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0039|cit39","unstructured":"Evaluation of AL-78898A in exudative age-related macular degeneration (RACE) clinicaltrials.gov\/ct2\/show\/NCT01157065"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0040|cit40","unstructured":"Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration (AMD) clinicaltrials.gov\/ct2\/show\/NCT01624636"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0041|cit41","unstructured":"ZIMURA in combination with LUCENTIS in patients with neovascular age related macular degeneration (NVAMD) clinicaltrials.gov\/ct2\/show\/NCT03362190"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0042|cit42","unstructured":"Safety and efficacy of IONIS-FB-Lrx in up to 120 patients 55 and older with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) clinicaltrials.gov\/ct2\/show\/NCT03446144"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0043|cit43","unstructured":"GOLDEN STUDY: a study to assess safety and efficacy of multiple doses of IONIS-FB-LRx in participants with geographic atrophy secondary to age-related macular degeneration (AMD) clinicaltrials.gov\/ct2\/show\/NCT03815825"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0044|cit44","unstructured":"A phase 3 safety and efficacy study of intravitreal administration of zimura (complement C5 inhibitor) clinicaltrials.gov\/ct2\/show\/NCT04435366"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0045|cit45","unstructured":"EXPLORE: a phase II study to evaluate the safety and efficacy of two doses of GT005 (EXPLORE) clinicaltrials.gov\/ct2\/show\/NCT04437368"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0046|cit46","unstructured":"A study of NGM621 in participants with geographic atrophy (CATALINA) clinicaltrials.gov\/ct2\/show\/NCT04465955"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0047|cit47","unstructured":"HORIZON: a phase II study to evaluate the safety and efficacy of two doses of GT005 clinicaltrials.gov\/ct2\/show\/NCT04566445"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0048|cit48","unstructured":"A multiple dose study of repeat intravitreal injections of GEM103 in dry age-related macular degeneration clinicaltrials.gov\/ct2\/show\/NCT04643886"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0049|cit49","unstructured":"A study investigating the efficacy and safety of intravitreal injections of ANX007 in patients with geographic atrophy (ARCHER) clinicaltrials.gov\/ct2\/show\/NCT04656561"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0050|cit50","unstructured":"A study of IBI302 in patients with nAMD clinicaltrials.gov\/ct2\/show\/NCT04820452"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0051|cit51","unstructured":"A study of danicopan in participants with geographic atrophy secondary to age-related macular degeneration clinicaltrials.gov\/ct2\/show\/NCT05019521"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0052|cit52","unstructured":"A masked, placebo-controlled study to assess iptacopan in age-related macular degeneration clinicaltrials.gov\/ct2\/show\/NCT05230537"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Progress in Retinal and Eye Research"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1167\/iovs.06-0761","article-title":"Anxiety and depression prevalence rates in age-related macular degeneration","volume":"48","author":"Augustin","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"15565","DOI":"10.1038\/s41598-022-19413-z","article-title":"Prediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learning","volume":"12","author":"Balaskas","year":"2022","journal-title":"Scientific Reports"},{"issue":"10","key":"10.1002\/14651858.CD009300.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","article-title":"Visual acuity as an outcome measure in clinical trials of retinal diseases","volume":"114","author":"Beck","year":"2007","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2009.08.003","article-title":"The dynamic nature of Bruch's membrane","volume":"29","author":"Booij","year":"2010","journal-title":"Progress in Retinal and Eye Research"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4049\/jimmunol.174.1.491","article-title":"Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization","volume":"174","author":"Bora","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0059|cit59","unstructured":"Boutron I Page MJ Higgins JPT Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0061|cit61","first-page":"473","article-title":"Vision and quality-of-life","volume":"97","author":"Brown","year":"1999","journal-title":"Transactions of the American Ophthalmological Society"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ajo.2020.05.029","article-title":"Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration","volume":"218","author":"Brown","year":"2020","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.immuni.2017.01.006","article-title":"Complement factor H inhibits CD47-mediated resolution of inflammation","volume":"46","author":"Calippe","year":"2017","journal-title":"Immunity"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1440-1827.2011.02695.x","article-title":"Macrophage polarization in the maculae of age-related macular degeneration: a pilot study","volume":"61","author":"Cao","year":"2011","journal-title":"Pathology International"},{"issue":"10","key":"10.1002\/14651858.CD009300.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"ARVO E","DOI":"10.1167\/iovs.62.10.34","article-title":"Hyperreflective foci, optical coherence tomography progression indicators in age-related macular degeneration, include transdifferentiated retinal pigment epithelium","volume":"62","author":"Cao","year":"2021","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"11","key":"10.1002\/14651858.CD009300.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/sctm.20-0211","article-title":"Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function","volume":"9","author":"Cerniauskas","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Chakravarthy","year":"2010","journal-title":"BMC Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1167\/iovs.03-0661","article-title":"Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study","volume":"45","author":"Chia","year":"2004","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajo.2018.02.012","article-title":"Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints","volume":"189","author":"Cocce","year":"2018","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ophtha.2007.04.016","article-title":"Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999","volume":"115","author":"Coleman","year":"2008","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009300.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","article-title":"Prevalence of age-related macular degeneration in Europe: The past and the future","volume":"124","author":"Colijn","year":"2017","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamaophthalmol.2021.1407","article-title":"Enlargement of geographic atrophy from first diagnosis to end of life","volume":"139","author":"Colijn","year":"2021","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Copland DA Theodoropoulou S Liu J Dick AD A perspective of AMD through the eyes of immunology Investigative Ophthalmology and Visual Science 2018 59 4 AMD83 92","DOI":"10.1167\/iovs.18-23893"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0075|cit75","unstructured":"Covidence Veritas Health Innovation"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0076|cit76","first-page":"100114","article-title":"Incidence and prevalence of neovascular age-related macular degeneration in France between 2008 and 2018: The LANDSCAPE study","volume":"2","author":"Creuzot-Garcher","year":"2022","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases","volume":"58","author":"Csaky","year":"2017","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0078|cit78","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022\u00a0 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.296.3.301","article-title":"Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration","volume":"296","author":"Despriet","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjo.73.4.297","article-title":"Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report","volume":"73","author":"Duvall-Young","year":"1989","journal-title":"British Journal of Ophthalmology"},{"issue":"5720","key":"10.1002\/14651858.CD009300.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Wilkinson","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","article-title":"Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26","volume":"131","author":"Feuer","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009300.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: A systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Global Health"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12874-018-0547-1","article-title":"Heckman imputation models for binary or continuous MNAR outcomes and MAR predictors","volume":"18","author":"Galimard","year":"2018","journal-title":"BMC Medical Research Methodology"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nature Genetics"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0089|cit89","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.preteyeres.2017.06.002","article-title":"On phagocytes and macular degeneration","volume":"61","author":"Guillonneau","year":"2017","journal-title":"Progress in Retinal and Eye Research"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/ICU.0b013e32810c8df4","article-title":"Age-related macular degeneration: the costs to society and the patient","volume":"18","author":"Gupta","year":"2007","journal-title":"Current Opinion in Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","article-title":"Protein PEGylation for cancer therapy: bench to bedside","volume":"13","author":"Gupta","year":"2019","journal-title":"Journal of Cell Communication and Signaling"},{"issue":"20","key":"10.1002\/14651858.CD009300.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5720","key":"10.1002\/14651858.CD009300.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"ARVO E","DOI":"10.1167\/iovs.61.6.18","article-title":"Rare genetic variants in complement factor I lead to low FI plasma levels resulting in increased risk of age-related macular degeneration","volume":"61","author":"Hallam","year":"2020","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7_4","volume-title":"Regression Modeling Strategies","author":"Harrell","year":"2015"},{"issue":"5","key":"10.1002\/14651858.CD009300.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bjo.2005.086595","article-title":"Impact of age related macular degeneration on quality of life","volume":"90","author":"Hassell","year":"2006","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/opo.12675","article-title":"Risk factors for progression of age-related macular degeneration","volume":"40","author":"Heesterbeek","year":"2020","journal-title":"Ophthalmic and Physiological Optics"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.oret.2020.01.019","article-title":"Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmology Retina"},{"issue":"7414","key":"10.1002\/14651858.CD009300.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0102|cit102","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0105|cit105","unstructured":"Hodge S Eccles F Loneliness, Social Isolation and Sight Loss: A literature review conducted for Thomas Pocklington Trust. Lancaster University eprints.lancs.ac.uk\/id\/eprint\/68597\/1\/loneliness_social_isolation_and_sight_loss_final_report_dec_13.pdf"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajpath.2013.04.008","article-title":"Complement component C3 plays a critical role in protecting the aging retina in a murine model of age-related macular degeneration","volume":"183","author":"Hoh Kam","year":"2013","journal-title":"American Journal of Pathology"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ije\/dyz032","article-title":"Accounting for missing data in statistical analyses: multiple imputation is not always the answer","volume":"48","author":"Hughes","year":"2019","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000484257","article-title":"Kallikrein cleaves C3 and activates complement","volume":"10","author":"Irmscher","year":"2018","journal-title":"Journal of Innate Immunity"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0109|cit109","first-page":"Doc04","article-title":"Prevalence of depression, anxiety, adjustment disorders, and somatoform disorders in patients with age-related macular degeneration in Germany","volume":"15","author":"Jacob","year":"2017","journal-title":"German Medical Science"},{"issue":"22","key":"10.1002\/14651858.CD009300.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2010-08-297648","article-title":"Complement halts angiogenesis gone wild","volume":"116","author":"Kahr","year":"2010","journal-title":"Blood"},{"issue":"7809","key":"10.1002\/14651858.CD009300.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"16","key":"10.1002\/14651858.CD009300.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"12886","DOI":"10.1074\/jbc.M112.345082","article-title":"Inhibiting alternative pathway complement activation by targeting the factor D exosite","volume":"287","author":"Wu","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"10.1002\/14651858.CD009300.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1167\/iovs.12-10797","article-title":"Mapping the differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera","volume":"53","author":"Keenan","year":"2012","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD009300.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0962280206075304","article-title":"Multiple imputation: current perspectives","volume":"16","author":"Kenward","year":"2007","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"100936","DOI":"10.1016\/j.preteyeres.2020.100936","article-title":"Targeting complement components C3 and C5 for the retina: key concepts and lingering questions","volume":"83","author":"Kim","year":"2021","journal-title":"Progress in Retinal and Eye Research"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"k3802","DOI":"10.1136\/bmj.k3802","article-title":"Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews","volume":"362","author":"Kirkham","year":"2018","journal-title":"BMJ"},{"issue":"5720","key":"10.1002\/14651858.CD009300.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/leu.2009.271","article-title":"Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytes","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1002\/14651858.CD009300.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","article-title":"Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis","volume":"104","author":"Li","year":"2020","journal-title":"British Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archophthalmol.2009.198","article-title":"Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26","volume":"127","author":"Lindblad","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009300.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jamaophthalmol.2015.126","article-title":"Clinicopathological correlation of outer retinal tubulation in age-related macular degeneration","volume":"133","author":"Litts","year":"2015","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2017.12.023","article-title":"Genome-wide association study reveals variants in CFH and CFHR4 associated with systemic complement activation: Implications in age-related macular degeneration","volume":"125","author":"Lor\u00e9s-Motta","year":"2018","journal-title":"Ophthalmology"},{"issue":"18","key":"10.1002\/14651858.CD009300.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1074\/jbc.M110.204701","article-title":"Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization","volume":"286","author":"Lyzogubov","year":"2011","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.smim.2013.04.002","article-title":"Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis","volume":"25","author":"Mastellos","year":"2013","journal-title":"Seminars in Immunology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1167\/iovs.10-6075","article-title":"Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry","volume":"52","author":"Meleth","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0128|cit128","unstructured":"Minassian D Reidy A Future Sight Loss UK 2: An epidemiological and economic model for sight loss in the decade 2010-2020 www.rnib.org.uk\/professionals\/health-social-care-education-professionals\/knowledge-and-research-hub\/knowledge-and-research\/future-sight-loss-uk-2\/"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2017.05.028","article-title":"The link between morphology and complement in ocular disease","volume":"89","author":"Mohlin","year":"2017","journal-title":"Molecular Immunology"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.imbio.2015.04.006","article-title":"The membrane attack complex as an inflammatory trigger","volume":"221","author":"Morgan","year":"2016","journal-title":"Immunobiology"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","article-title":"Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States","volume":"138","author":"Mulligan","year":"2020","journal-title":"JAMA Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaophthalmol.2021.6067","article-title":"Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the FILLY randomized clinical trial","volume":"140","author":"Nittala","year":"2022","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1073\/pnas.0408835103","article-title":"Drusen complement components C3a and C5a promote choroidal neovascularization","volume":"103","author":"Nozaki","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1002\/14651858.CD009300.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.976","article-title":"A rare penetrant mutation in CFH confers high risk of age-related macular degeneration","volume":"43","author":"Raychaudhuri","year":"2011","journal-title":"Nature Genetics"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0135|cit135","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD009300.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/ATVBAHA.114.304927","article-title":"Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate-salt mice","volume":"35","author":"Ruan","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"Pt 5","key":"10.1002\/14651858.CD009300.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/eye.1988.106","article-title":"Evolution of geographic atrophy of the retinal pigment epithelium","volume":"2","author":"Sarks","year":"1988","journal-title":"Eye"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/IAE.0000000000000471","article-title":"Outer retinal tubulation in advanced age-related macular degeneration: optical coherence tomographic findings correspond to histology","volume":"35","author":"Schaal","year":"2015","journal-title":"Retina"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ajo.2012.04.017","article-title":"Patterns and costs associated with progression of age-related macular degeneration","volume":"154","author":"Schmier","year":"2012","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000445217","article-title":"Modeling visual acuity in geographic atrophy secondary to age-related macular degeneration","volume":"235","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1002\/14651858.CD009300.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/ng.2741","article-title":"Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration","volume":"45","author":"Seddon","year":"2013","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/bjophthalmol-2011-300193","article-title":"Age-related macular degeneration: the importance of family history as a risk factor","volume":"96","author":"Shahid","year":"2012","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009300.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0008-4182(00)80077-0","article-title":"Converting visual acuity to utilities","volume":"35","author":"Sharma","year":"2000","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"34","key":"10.1002\/14651858.CD009300.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.1073\/pnas.1121309109","article-title":"Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids","volume":"109","author":"Shaw","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0147|cit147","unstructured":"Simkiss P Dennison D Edwards E Edwards R Flynn K Lee H The State of the Nation Eye Health 2016. RNIB www.rnib.org.uk\/stateofthenation"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.survophthal.2005.02.007","article-title":"Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment","volume":"50","author":"Slakter","year":"2005","journal-title":"Survey of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archopht.125.9.1249","article-title":"Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study","volume":"125","author":"Soubrane","year":"2007","journal-title":"Archives of Ophthalmology"},{"issue":"16","key":"10.1002\/14651858.CD009300.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/hmg\/ddm146","article-title":"Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration","volume":"16","author":"Spencer","year":"2007","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/aje\/kwq137","article-title":"Strategies for multiple imputation in longitudinal studies","volume":"172","author":"Spratt","year":"2010","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2021.02.031","article-title":"Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan","volume":"227","author":"Steinle","year":"2021","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009300.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/09286580701502970","article-title":"Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19","volume":"14","author":"Submacular Surgery Trials Research Group","year":"2007","journal-title":"Ophthalmic Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0161-6420(99)90340-8","article-title":"Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration","volume":"106","author":"Sunness","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ajo.2005.07.040","article-title":"Long-term follow-up of fixation patterns in eyes with central scotomas from geographic atrophy that is associated with age-related macular degeneration","volume":"140","author":"Sunness","year":"2005","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.survophthal.2020.10.008","article-title":"Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants","volume":"66","author":"Tzoumas","year":"2021","journal-title":"Survey of Ophthalmology"},{"issue":"16","key":"10.1002\/14651858.CD009300.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1093\/hmg\/ddac060","article-title":"Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK Biobank","volume":"31","author":"Tzoumas","year":"2022","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0158|cit158","first-page":"355","article-title":"Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass","volume":"74","author":"Undar","year":"2002","journal-title":"Annals of Cardiothoracic Surgery"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"e0197670","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration \u2014 a cost-effectiveness analysis from a societal perspective","volume":"13","author":"Asten","year":"2018","journal-title":"PLOS One"},{"issue":"7","key":"10.1002\/14651858.CD009300.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/ng.2640","article-title":"A functional variant in the\u00a0CFI\u00a0gene confers a high risk of age-related macular degeneration","volume":"45","author":"de Ven","year":"2013","journal-title":"Nature Genetics"},{"issue":"11","key":"10.1002\/14651858.CD009300.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","article-title":"The association between intravitreal steroids and post-injection endophthalmitis rates","volume":"122","author":"VanderBeek","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009300.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bjo.2004.047498","article-title":"Impact of unilateral and bilateral vision loss on quality of life","volume":"89","author":"Vu","year":"2005","journal-title":"British Journal of Ophthalmology"},{"issue":"7367","key":"10.1002\/14651858.CD009300.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nature10449","article-title":"Complement factor H binds malondialdehyde epitopes and protects from oxidative stress","volume":"478","author":"Weismann","year":"2011","journal-title":"Nature"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","article-title":"Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy","volume":"45","author":"Whitmore","year":"2015","journal-title":"Progress in Retinal and Eye Research"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12920-020-00760-7","article-title":"Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease","volume":"13","author":"Winkler","year":"2020","journal-title":"BMC Medical Genomics"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2013.01.068","article-title":"The economic burden of vision loss and eye disorders among the United States population younger than 40 years","volume":"120","author":"Wittenborn","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Global Health"},{"issue":"8","key":"10.1002\/14651858.CD009300.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.4049\/jimmunol.1701668","article-title":"Contribution of adipose-derived factor D\/adipsin to complement alternative pathway activation: Lessons from lipodystrophy","volume":"200","author":"Wu","year":"2018","journal-title":"Journal of Immunology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009300.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molmed.2009.12.001","article-title":"Complement in neuroprotection and neurodegeneration","volume":"16","author":"Yanamadala","year":"2010","journal-title":"Trends in Molecular Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009300.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMoa072618","article-title":"Complement C3 variant and the risk of age-related macular degeneration","volume":"357","author":"Yates","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009300.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Molecular Immunology"},{"issue":"9","key":"10.1002\/14651858.CD009300.pub3-BIB0173|cit173","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009300","article-title":"Complement inhibitors for age-related macular degeneration","author":"Williams","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009300.pub3-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009300.pub2","article-title":"Complement inhibitors for age-related macular degeneration","author":"Williams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:49:00Z","timestamp":1758584940000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009300.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":174,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009300.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}